CA2714880C - Nouveau biomarqueur de tumeur - Google Patents

Nouveau biomarqueur de tumeur Download PDF

Info

Publication number
CA2714880C
CA2714880C CA2714880A CA2714880A CA2714880C CA 2714880 C CA2714880 C CA 2714880C CA 2714880 A CA2714880 A CA 2714880A CA 2714880 A CA2714880 A CA 2714880A CA 2714880 C CA2714880 C CA 2714880C
Authority
CA
Canada
Prior art keywords
hsp90a
cancer
polypeptide
plasma
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2714880A
Other languages
English (en)
Other versions
CA2714880A1 (fr
Inventor
Yongzhang Luo
Xiaomin SONG
Xiaofeng Wang
Wei Zhuo
Guodong Chang
Yan Fu
Original Assignee
Tsinghua University
Protgen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tsinghua University, Protgen Ltd filed Critical Tsinghua University
Priority to CA2714880A priority Critical patent/CA2714880C/fr
Publication of CA2714880A1 publication Critical patent/CA2714880A1/fr
Application granted granted Critical
Publication of CA2714880C publication Critical patent/CA2714880C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention concerne le diagnostic et le traitement du cancer, plus particulièrement un procédé de diagnostic de la présence ou dune métastase dun cancer par détection de plasma Hsp90.alpha. ayant une séquence dacides aminés de SEQ ID NO. 1 comme marqueur de tumeur. En outre, la présente invention concerne également un procédé pour le traitement du cancer et dune métastase.
CA2714880A 2010-09-15 2010-09-15 Nouveau biomarqueur de tumeur Active CA2714880C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2714880A CA2714880C (fr) 2010-09-15 2010-09-15 Nouveau biomarqueur de tumeur

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA2714880A CA2714880C (fr) 2010-09-15 2010-09-15 Nouveau biomarqueur de tumeur

Publications (2)

Publication Number Publication Date
CA2714880A1 CA2714880A1 (fr) 2012-03-15
CA2714880C true CA2714880C (fr) 2018-11-20

Family

ID=45816187

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2714880A Active CA2714880C (fr) 2010-09-15 2010-09-15 Nouveau biomarqueur de tumeur

Country Status (1)

Country Link
CA (1) CA2714880C (fr)

Also Published As

Publication number Publication date
CA2714880A1 (fr) 2012-03-15

Similar Documents

Publication Publication Date Title
KR101587932B1 (ko) 네트린-1 활성을 이용한 항암 화합물의 스크리닝
CN107098970B (zh) 结合细胞内prl-1多肽或prl-3多肽的抗体
AU2010268979B2 (en) New tumor marker
KR20140107615A (ko) 엑소좀 검출용 모노클로날 항체
DK2743697T3 (en) METHODS OF IN VITRO DIAGNOSTICS OF INVASIVE CARCINOMS
WO2008115300A1 (fr) Phosphorylation de c-kit dans les cas de cancer
JP2022180377A (ja) 受容体タンパク質を標的とする治療薬、検査薬、受容体タンパク質に結合する抗体、及び分子標的薬のスクリーニング方法
CN103694332B (zh) 一种新的肿瘤标志物
Jiang et al. Peptide mimic isolated by autoantibody reveals human arrest defective 1 overexpression is associated with poor prognosis for colon cancer patients
US9815906B2 (en) Method of inhibiting or treating cancer metastasis
JP2010151800A (ja) 生活習慣病及び／又は癌の診断剤
KR102429562B1 (ko) 간세포암 진단용 바이오마커 세레브론 및 이에 특이적인 신규한 단일클론항체
US8232069B2 (en) Antibody directed against PAP2a and use thereof for diagnostic and therapeutic purposes
CA2714880C (fr) Nouveau biomarqueur de tumeur
AU2014203702B2 (en) New tumor marker
HK1166329A (en) New tumor marker
HK1166329B (en) New tumor marker
JPWO2018034332A1 (ja) ＥｐｈＡ２ Ｎ末端フラグメント抗体
HK1152951B (en) Novel tumor marker
WO2012133994A1 (fr) Procédé de dépistage destiné à un agent de traitement du cancer utilisant une interaction entre le pauf et l'un de ses partenaires de liaison
WO2007037532A9 (fr) Application therapeutique ou diagnostique du gene srms

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150401

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - STANDARD

Year of fee payment: 14

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240910

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240910

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240910

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 15TH ANNIV.) - STANDARD

Year of fee payment: 15

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250812

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250818